Alzai Health (TSXV:ALZI) LT-Debt-to-Total-Asset: 0.00 (As of Jan. 2026)


TSXV:ALZI Alzai Health Corp TSXV:ALZI
9 GF Score
Price C$0.50
! 1 Warning Sign
View Full Analysis

What is Alzai Health LT-Debt-to-Total-Asset?

Alzai Health TSXV:ALZI 9 LT-Debt-to-Total-Asset is 0.00 as of Jan. 2026. GuruFocus rates TSXV:ALZI with a GF Score™ of 9/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Alzai Health's long-term debt to total assests ratio for the quarter that ended in Jan. 2026 was 0.00.

Alzai Health's long-term debt to total assets ratio stayed the same from Jan. 2025 (0.00) to Jan. 2026 (0.00).

Alzai Health  (TSXV:ALZI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Alzai Health LT-Debt-to-Total-Asset Related Terms

Alzai Health LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Alzai Health's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alzai Health LT-Debt-to-Total-Asset Chart

Alzai Health Annual Data
Trend
LT-Debt-to-Total-Asset

Alzai Health Quarterly Data
Jan25 Apr25 Jul25 Oct25 Jan26
LT-Debt-to-Total-Asset 0.00 0.00 0.00 0.00 0.00
TSXV:ALZI
9GF Score
Alzai Health Corp TSXV:ALZI
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alzai Health LT-Debt-to-Total-Asset Calculation

Alzai Health's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in . 20 is calculated as

LT Debt to Total Assets (A: . 20 )=Long-Term Debt & Capital Lease Obligation (A: . 20 )/Total Assets (A: . 20 )
=/
=

Alzai Health's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2026 is calculated as

LT Debt to Total Assets (Q: Jan. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jan. 2026 )/Total Assets (Q: Jan. 2026 )
=0/1.016
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Alzai Health (TSXV:ALZI) has a LT-Debt-to-Total-Asset of 0.00 as of Jan. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Alzai Health and its competitors.
Is Alzai Health's LT-Debt-to-Total-Asset too high?
Alzai Health's current LT-Debt-to-Total-Asset is 0.00. Overall, Alzai Health has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Alzai Health's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Alzai Health's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Alzai Health and its competitors. Alzai Health's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alzai Health stock overvalued right now?
Alzai Health (TSXV:ALZI) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Alzai Health's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Alzai Health (TSXV:ALZI), the current LT-Debt-to-Total-Asset is 0.00 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alzai Health Business Description

Address 22 Adelaide Street West, Suite 3400, Toronto, ON, CAN, M5H 4E3
Alzai Health Corp is a healthcare company focused on comprehensive health solutions. It is an AI-driven Alzheimer's disease risk screening platform, enabling disease prevention and early disease diagnosis to improve patient outcomes. The company uses low-cost, non-invasive, pre-existing biomarker data present in nearly all Electronic Medical Records of the relevant age demographic. It aims to address the unmet need in Alzheimer's screening, enabling early detection and mitigation driving to diagnosis, therapy or prevention.
9GF Score

Get the complete analysis for TSXV:ALZI

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.50
Price